CPV Specific Neutra™ Antibody Products

Are you struggling with extended timelines in antiviral drug discovery or facing challenges in neutralizing canine parvovirus (CPV)? Creative Biolabs' CPV-specific Neutra™ antibody products overcome these obstacles through advanced protein engineering and high-throughput epitope mapping, enabling rapid development of therapeutics with unmatched specificity and efficacy.

Introduction to CPV

Canine parvovirus (CPV) is a non-enveloped, single-stranded DNA virus belonging to the Parvoviridae family. First identified in 1978, CPV is highly contagious and primarily affects dogs, causing severe gastrointestinal distress, leukopenia, and life-threatening dehydration. Its rapid mutation rate and environmental resilience make it a persistent global veterinary health challenge.

• Basic Information

CPV exists in two pathogenic forms: CPV-2a and CPV-2b, differentiated by mutations in the viral capsid protein VP2. Transmission occurs via direct contact with infected feces or contaminated environments. The virus targets rapidly dividing cells in the intestinal epithelium, bone marrow, and lymphoid tissues, leading to systemic collapse if left untreated.

• Structural Insights

The CPV capsid includes 60 copies of VP2 organized in an icosahedral symmetry. VP2 determines host tropism and receptor binding, with critical residues (e.g., Asp-300 and Tyr-324) mediating attachment to the canine transferrin receptor (TfR). Cryo-EM studies reveal that conformational shifts in VP2 enable endosomal escape, facilitating viral entry into host cells.

• Host Signaling Pathways

CPV hijacks host cell machinery by modulating pathways such as:

- TfR-Mediated Endocytosis: Viral entry via clathrin-coated pits.

- NF-κB Activation: Promotes pro-inflammatory cytokine release, exacerbating tissue damage.

- p53 Dysregulation: Induces apoptosis in intestinal crypt cells, impairing mucosal regeneration.

Fig.1 CPV-infection-mediated apoptosis and virus-host-cell interactions.¹

• Associated Pathologies

CPV infection manifests as hemorrhagic gastroenteritis, characterized by vomiting, bloody diarrhea, and immunosuppression. In untreated cases, mortality rates surpass 90%, especially in puppies and sick dogs.

Applications of Anti-CPV Neutralizing Antibodies

• Diagnostic Assay Development

CPV-Specific Antibodies enable rapid detection of viral antigens in fecal samples using ELISA or lateral flow assays. Their high specificity minimizes cross-reactivity with non-target pathogens, ensuring accurate diagnosis even in early-stage infections.

• Therapeutic Intervention

Monoclonal antibodies targeting CPV reduce viral load in preclinical models by blocking TfR binding. Administered intravenously, these antibodies shorten recovery times and mitigate mortality in acute cases.

• Vaccine Efficacy Evaluation

Quantify neutralizing antibody titers in vaccinated animals to assess immune protection. Our antibodies serve as gold-standard reagents in virus neutralization tests (VNTs), supporting vaccine lot-release and regulatory compliance.

• Antiviral Drug Screening

Use CPV-specific antibodies in high-throughput screens to identify small molecules or peptides that inhibit VP2-receptor interactions, accelerating lead compound discovery.

Anti-CPV Neutralizing Antibodies

Creative Biolabs' CPV-Specific Antibodies target conformational epitopes on VP2, disrupting viral attachment and entry. These antibodies exhibit:

- High Affinity (KD <1 nM): Validated via surface plasmon resonance (SPR).

- Cross-Reactivity: Neutralize CPV-2a, CPV-2b, and emerging variants.

- Thermostability: Maintain activity under diverse storage conditions for reliable assay performance.

Creative Biolabs delivers rigorously validated CPV-specific Neutra™ antibodies tailored to advance your antiviral research. With batch-to-batch consistency and customizable formats (e.g., Fab fragments, IgG), our products empower breakthroughs in diagnostics, therapeutics, and vaccine development.

Contact our team today to discuss your CPV project and request product specifications.

REFERENCE

1. Zhou, Hongzhuan, et al. "Overview of recent advances in canine parvovirus research: current status and future perspectives." Microorganisms 13.1 (2024): 47. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/microorganisms13010047